Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral Blood Stem Cells

Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation

Bone Marrow Transplantation volume 26, pages 831–836 (2000)Cite this article

Abstract

High-dose chemotherapy followed by CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is used for the treatment of primary refractory or relapsed Hodgkin’s and non-Hodgkin’s lymphomas. The CD34+ enrichment procedure, while reducing tumor burden, may compromise immunological reconstitution in the transplanted patient and result in increased rates of post-transplant infection. We compared infectious complications in patients with lymphoma who were treated with high-dose chemotherapy and supported either with CD34+ enriched PBPC (n = 19) or unmanipulated PBPCs (n = 24). Analysis was limited to patients discharged from initial hospitalization for transplantation with a minimum of 1 year follow-up and free of lymphoma recurrence. We found a statistically significant increase in the number of patients with one or more infectious events in the CD34+transplant group (14/19) compared with the unmanipulated PBPC group (9/24, P < 0.01). Greater numbers of patients with two or more infectious events were observed in the CD34+ group (7/19 vs 2/24, P < 0.03) and an increased incidence of bacterial infections was observed in the CD34+ group (10/19 vs 5/24, P < 0.05). Two deaths due to infectious complications were observed in the CD34+ group. There was no significant difference in blood lymphocyte or monocyte recovery between the groups. These data demonstrate a significant increase in the long-term incidence of infectious events in lymphoma patients transplanted with autologous CD34+ enriched PBPCs compared to unmanipulated PBPCs. Thus, patients who undergo CD34+ enriched PBPC transplantation should be followed closely for infectious complications and prolonged infectious prophylaxis should be considered. Bone Marrow Transplantation (2000) 26, 831–836.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Lazarus HM, Crilley P, Ciobanu N et al. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma J Clin Oncol 1992 10: 1682–1689

    Article  CAS  Google Scholar 

  2. Sharp JG, Kessinger A, Mann DA et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin’s lymphoma based on the presence of tumor in the marrow or infused hematopoetic harvest J Clin Oncol 1996 14: 214–219

    Article  CAS  Google Scholar 

  3. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma Blood 1995 86: 390–397

    CAS  PubMed  Google Scholar 

  4. Koc ON, Gerson SL, Phillips GL et al. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment Bone Marrow Transplant 1998 21: 337–343

    Article  CAS  Google Scholar 

  5. Nachbaur D, Fink F-M, Nussbaumer W et al. CD34+-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single-centre experience Bone Marrow Transplant 1997 20: 827–834

    Article  CAS  Google Scholar 

  6. Miyamoto T, Gondo H, Miyoshi Y . Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma Br J Haematol 1998 100: 348–350

    Article  CAS  Google Scholar 

  7. Nachbaur D, Kropshofer G, Feichtinger H et al. Cryptospordiosis after CD34-selected autologous peripheral blood stem cell transplantation Bone Marrow Transplant 1997 19: 1261–1263

    Article  CAS  Google Scholar 

  8. Holmberg L, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation Blood 1999 94: 4029–4035

    CAS  PubMed  Google Scholar 

  9. Lazarus HM, Pecora AL, Shea TC et al. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of product at 4°C does not affect outcome Bone Marrow Transplant 2000 25: 559–566

    Article  CAS  Google Scholar 

  10. Bomberger C, Jairam-Singh M, Rodney G et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors Blood 1998 91: 2588–2600

    CAS  PubMed  Google Scholar 

  11. Kiessel S, Pezzutto A, Korbling M et al. Autologous peripheral blood stem cell transplantation: analysis of autografted cells and lymphocyte recovery Transplant Proc 1989 21: 3084–3088

    Google Scholar 

  12. Talmadge JE, Reed EC, Kessinger A et al. Immunologic attributes of cytokine mobilized blood stem cells and recovery following transplantation Bone Marrow Transplant 1996 17: 101–109

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Public Health Service grant P30CA43703.

Author information

Authors and Affiliations

  1. Ireland Cancer Center and Department of Medicine, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH, USA

    J Friedman & HM Lazarus

  2. Case Western Reserve University, BRB-3 Hematology/Oncology, 10900 Euclid Ave, Cleveland, OH 44106, USA

    ON Koç

Authors
  1. J Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. HM Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. ON Koç
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedman, J., Lazarus, H. & Koç, O. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 26, 831–836 (2000). https://doi.org/10.1038/sj.bmt.1702623

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702623

Keywords

This article is cited by

Search

Advanced search

Quick links